Quest Diagnostics hits 52-week high amid analyst upgrades

Quest Diagnostics (NYSE: DGX) reached a new 52-week high following a series of analyst upgrades. Truist Financial raised its price target for the stock from $250.00 to $260.00, while JPMorgan Chase & Co. increased its objective from $220.00 to $250.00. Other financial institutions, including Barclays and Argus, also issued updated price targets, contributing to a consensus rating of “Moderate Buy.”

Separately, the company announced it will release its third-quarter 2026 financial results on Thursday, October 22, 2026, before the market opens. A quarterly conference call is scheduled for 8:30 a.m. Eastern Time on that date to discuss the results.